Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03310879 |
|
Recruitment Status :
Recruiting
First Posted : October 16, 2017
Last Update Posted : January 10, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 1, 2023 |
| Estimated Study Completion Date : | April 30, 2025 |